Stimulation of β-adrenoceptors up-regulates cardiac expression of galectin-3 and BIM through the Hippo signalling pathway

Br J Pharmacol. 2019 Jul;176(14):2465-2481. doi: 10.1111/bph.14674. Epub 2019 May 30.

Abstract

Background and purpose: Expression of the pro-fibrotic galectin-3 and the pro-apoptotic BIM is elevated in diseased heart or after β-adrenoceptor stimulation, but the underlying mechanisms are unclear. This question was addressed in the present study.

Experimental approach: Wild-type mice and mice with cardiac transgenic expression of β2 -adrenoceptors, mammalian sterile-20 like kinase 1 (Mst1) or dominant-negative Mst1, and non-specific galectin-3 knockout mice were used. Effects of the β-adrenoceptor agonist isoprenaline or β-adrenoceptor antagonists were studied. Rat cardiomyoblasts (H9c2) were used for mechanistic exploration. Biochemical assays were performed.

Key results: Isoprenaline treatment up-regulated expression of galectin-3 and BIM, and this was inhibited by non-selective or selective β-adrenoceptor antagonists (by 60-70%). Cardiac expression of galectin-3 and BIM was increased in β2 -adrenoceptor transgenic mice. Isoprenaline-induced up-regulation of galectin-3 and BIM was attenuated by Mst1 inactivation, but isoprenaline-induced galectin-3 expression was exaggerated by transgenic Mst1 activation. Pharmacological or genetic activation of β-adrenoceptors induced Mst1 expression and yes-associated protein (YAP) phosphorylation. YAP hyper-phosphorylation was also evident in Mst1 transgenic hearts with up-regulated expression of galectin-3 (40-fold) and BIM as well as up-regulation of many YAP-target genes by RNA sequencing. In H9c2 cells, isoprenaline induced YAP phosphorylation and expression of galectin-3 and BIM, effects simulated by forskolin but abolished by PKA inhibitors, and YAP knockdown induced expression of galectin-3 and BIM.

Conclusions and implications: Stimulation of cardiac β-adrenoceptors activated the Mst1/Hippo pathway leading to YAP hyper-phosphorylation with enhanced expression of galectin-3 and BIM. This signalling pathway would have therapeutic potential.

Linked articles: This article is part of a themed section on Adrenoceptors-New Roles for Old Players. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.14/issuetoc.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Agonists / pharmacology
  • Adrenergic beta-Antagonists / pharmacology
  • Animals
  • Bcl-2-Like Protein 11 / antagonists & inhibitors
  • Bcl-2-Like Protein 11 / metabolism*
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / metabolism*
  • Carvedilol / pharmacology
  • Cell Line
  • Dose-Response Relationship, Drug
  • Galectin 3 / antagonists & inhibitors
  • Galectin 3 / deficiency
  • Galectin 3 / metabolism*
  • Isoproterenol / administration & dosage
  • Isoproterenol / pharmacology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mice, Transgenic
  • Propanolamines / pharmacology
  • Propranolol / pharmacology
  • Rats
  • Receptors, Adrenergic, beta-3 / genetics
  • Receptors, Adrenergic, beta-3 / metabolism*
  • Signal Transduction* / drug effects
  • Up-Regulation* / drug effects

Substances

  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Bcl-2-Like Protein 11
  • Bcl2l11 protein, mouse
  • Galectin 3
  • Lgals3 protein, mouse
  • Propanolamines
  • Receptors, Adrenergic, beta-3
  • Carvedilol
  • ICI 118551
  • Propranolol
  • Isoproterenol